Charleston News Online

Spinal Muscular Atrophy Pipeline Analysis, 2022 – Clinical and Non-Clinical Trials, Emerging Drugs, and Therapeutic Assessment | Key Players – Novartis, Cytokinetics, Astellas, Biogen, Novartis, Roche

Spinal Muscular Atrophy Pipeline Analysis, 2022 – Clinical and Non-Clinical Trials, Emerging Drugs, and Therapeutic Assessment | Key Players – Novartis, Cytokinetics, Astellas, Biogen, Novartis, Roche

June 23
00:20 2022
Spinal Muscular Atrophy Pipeline Analysis, 2022 - Clinical and Non-Clinical Trials, Emerging Drugs, and Therapeutic Assessment | Key Players - Novartis, Cytokinetics, Astellas, Biogen, Novartis, Roche
Delveinsight Business Research LLP
‚ÄúSpinal Muscular Atrophy Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Spinal Muscular Atrophy Pipeline Analysis

Spinal Muscular Atrophy Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Spinal Muscular Atrophy Treatment.

  • Spinal Muscular Atrophy key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Spinal Muscular Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight

Spinal Muscular Atrophy Therapeutics Landscape

The Spinal Muscular Atrophy pipeline possesses multiple potential drugs in late and mid-stage developments that are expected to be launched in the near future. 

Some of the key companies in the Spinal Muscular Atrophy Market include:

  • Novartis

  • Cytokinetics

  • Astellas

  • Biogen

  • Novartis

  • Hoffmann-La Roche

  • PTC Therapeutics 

  • Catalyst Pharmaceuticals 

And many others.

Spinal Muscular Atrophy Therapies covered in the report include:

  • BVS 857

  • SRK-015

  • Branaplam (LMI070)

  • Reldesemtiv (CK-2127107)

  • Amifampridine Phosphate (Firdapse)

And a few others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Spinal Muscular Atrophy Current Treatment Patterns

4. Spinal Muscular Atrophy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Spinal Muscular Atrophy Late Stage Products (Phase-III)

7. Spinal Muscular Atrophy Mid-Stage Products (Phase-II)

8. Spinal Muscular Atrophy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Spinal Muscular Atrophy Discontinued Products

13. Spinal Muscular Atrophy Product Profiles

14. Key Companies in the Spinal Muscular Atrophy Market

15. Key Products in the Spinal Muscular Atrophy Therapeutics Segment

16. Dormant and Discontinued Products

17. Spinal Muscular Atrophy Unmet Needs

18. Spinal Muscular Atrophy Future Perspectives

19. Spinal Muscular Atrophy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Brain Hemorrhage Market
“Brain Hemorrhage Market” report delivers an in-depth understanding of the Brain Hemorrhage, historical and forecasted epidemiology as well as the Brain Hemorrhage market trends in 7MM.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Author

admin

admin

Related Articles